GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Common Stock

AdAlta (ASX:1AD) Common Stock : A$45.56 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AdAlta Common Stock?

AdAlta's quarterly common stock increased from Dec. 2022 (A$41.01 Mil) to Jun. 2023 (A$42.18 Mil) and increased from Jun. 2023 (A$42.18 Mil) to Dec. 2023 (A$45.56 Mil).

AdAlta's annual common stock increased from Jun. 2021 (A$36.23 Mil) to Jun. 2022 (A$41.01 Mil) and increased from Jun. 2022 (A$41.01 Mil) to Jun. 2023 (A$42.18 Mil).


AdAlta Common Stock Historical Data

The historical data trend for AdAlta's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Common Stock Chart

AdAlta Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial 28.44 36.23 41.01 42.18 47.40

AdAlta Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.01 41.01 42.18 45.56 47.40

AdAlta Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


AdAlta Business Description

Traded in Other Exchanges
N/A
Address
2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083
AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta Headlines

No Headlines